Quick answer: Some peptide-based medicines, such as semaglutide (Wegovy) and tirzepatide (Zepbound), are FDA-approved for specific uses. Many peptides marketed for wellness, including BPC-157, are not FDA-approved drugs. Compounded peptides are not FDA-approved, and FDA has flagged safety concerns for several. "Research use only" products are not meant for people.
"Peptide" is a chemistry word, not a regulatory category
A peptide is a short chain of amino acids. That's chemistry. FDA doesn't regulate "peptides" as a group. It regulates specific products for specific uses. So "Are peptides FDA-approved?" has three different answers, depending on what you're holding:
- An FDA-approved drug that happens to be a peptide.
- A compounded preparation made by a pharmacy.
- A product sold "for research use" or "not for human consumption."
Bucket 1: FDA-approved peptide medicines
Some well-known medicines are peptides or peptide analogs. FDA approved Zepbound (tirzepatide) for chronic weight management in adults with obesity, or overweight with a weight-related condition, in November 2023. FDA later approved Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in certain adults with cardiovascular disease and obesity or overweight. These products went through FDA review of safety, effectiveness, and manufacturing quality for their labeled uses.
FDA approval is tied to the exact product and labeled indication. It does not cover look-alike versions made somewhere else.
Bucket 2: Compounded peptides
What compounding is
FDA explains that compounding can serve a real need, for example when a patient is allergic to a dye in an approved drug or can't swallow a tablet. Compounding is mainly done by licensed pharmacists in state-licensed pharmacies (503A) or in FDA-registered outsourcing facilities (503B).
What compounding is not
FDA states plainly: compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before they are marketed. A compounded drug also isn't a generic. Generics are FDA-approved and show therapeutic equivalence to a brand, and compounded drugs are not.
FDA's bulk-substance categories
Pharmacies compounding from raw ingredients ("bulk drug substances") work under federal rules and FDA interim policies. FDA keeps a public list called Category 2: substances nominated for compounding that FDA says may present significant safety risks.
On that page (content current as of April 22, 2026), FDA lists, for example:
- Ipamorelin acetate (503B Category 2, added September 2023). FDA cites possible immunogenicity and impurity risks.
- Kisspeptin-10 (503A Category 2, added September 2023). FDA notes no, or only limited, safety-related information.
The same page has a separate section of substances "previously in category 2" whose nominations were withdrawn by the nominators. That section includes BPC-157, thymosin alpha-1, GHK-Cu (injectable routes), AOD-9604, CJC-1295, thymosin beta-4 fragment (LKKTETQ), also known as TB-500, epitalon, and others. For BPC-157, FDA's text says compounded versions may pose immunogenicity risk for certain routes, raise impurity and characterization concerns, and that FDA "lacks sufficient information to know whether the drug would cause harm when administered to humans."
What "withdrawn" does not mean: a withdrawn nomination is not an approval. It also doesn't mean FDA found the substance safe. The rules here are technical and change over time, so treat any clinic that calls a wellness peptide "FDA-approved" with caution.
Bucket 3: "Research use only" products
FDA has warned companies that illegally sold unapproved drugs, including semaglutide, tirzepatide, and retatrutide, falsely labeled "for research purposes" or "not for human consumption." Retatrutide is investigational. FDA says it cannot be used in compounding under federal law and has not been found safe and effective for any condition. Research-labeled products bypass the protections of both FDA approval and licensed pharmacy compounding.
What the evidence looks like for a popular example
BPC-157 shows the gap between online buzz and evidence. A 2025 systematic review in HSS Journal (Hospital for Special Surgery) found 36 eligible studies on BPC-157 in orthopedic sports medicine: 35 preclinical and 1 clinical. The authors noted that BPC-157 lacks FDA approval and is banned in professional sports, even as clinicians and athletes increasingly use it. Animal data aren't human outcome data.
How to use this as a patient
Five questions for any peptide provider
- Is this an FDA-approved product, a compounded preparation, or something else?
- Which pharmacy prepares it, and is it state-licensed (503A) or an FDA-registered outsourcing facility (503B)?
- What does FDA's bulk-substance page say about this ingredient?
- What human evidence exists for my goal, and how strong is it?
- Is a licensed clinician evaluating me first and available afterward?
Our peptide provider vetting guide goes deeper. At Regen Therapy MD, a physician evaluates you first. Where peptides are prescribed, they ship only to states where we are licensed.
Frequently asked questions
Are peptides FDA-approved?
Some are. Peptide-based medicines like Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved for specific labeled uses. Many peptides marketed for wellness are not FDA-approved drugs. Compounded peptides of any kind are not FDA-approved, according to FDA.
Is BPC-157 FDA-approved?
No. BPC-157 is not an FDA-approved drug. FDA's bulk-substance page lists BPC-157 among substances previously in Category 2 whose nominations were withdrawn, and FDA states it lacks sufficient information to know whether it would cause harm in humans. A 2025 review found mostly animal studies.
Are compounded peptides legal?
Compounding is legal within federal and state rules, done by licensed pharmacies or FDA-registered outsourcing facilities. But compounded drugs are not FDA-approved, and FDA restricts certain substances. Whether a specific peptide can be compounded depends on detailed rules a pharmacist and physician should confirm.
What does "research use only" mean on peptides?
It means the product is not intended for people. FDA has warned companies that sold unapproved drugs, including semaglutide, tirzepatide, and retatrutide, falsely labeled "for research purposes" or "not for human consumption." These products skip FDA approval and licensed pharmacy oversight.
What is FDA Category 2?
Category 2 is FDA's list of bulk drug substances nominated for compounding that may present significant safety risks. As of April 2026, it includes ipamorelin acetate (503B) and kisspeptin-10 (503A). A separate section lists substances whose nominations were withdrawn.
Talk with a Regen Therapy MD physician
If you'd like to talk through whether any of these options fit your health history, start with a physician consult, not a product.
- Book a consult: https://book.mypatientnow.com/practice/TqZLiT
- Call: (424) 349-6008
- Cost: $295 consult (physician visit)
- Clinics: Beverly Hills and Santa Monica. Telehealth and peptide shipping are available only where we are licensed.
Sources
- U.S. FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- U.S. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- U.S. FDA. FDA Approves New Medication for Chronic Weight Management (Zepbound), November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- U.S. FDA. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (Wegovy), March 8, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID 40756949. https://pubmed.ncbi.nlm.nih.gov/40756949/
Educational disclaimer
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. It doesn't establish a doctor-patient relationship or confirm that you are a candidate for any therapy. Individual results vary, and no outcome is promised. Study figures are group results from the cited publications, not predictions for any individual. Compounded drugs are not FDA-approved, and FDA-approved brand products and compounded preparations are not interchangeable. Retatrutide is investigational. This article doesn't provide dosing or treatment protocols. Talk with a licensed clinician about your own situation. If you have a medical emergency, call 911.
.svg)
